keyword
MENU ▼
Read by QxMD icon Read
search

Levonorgestrel

keyword
https://www.readbyqxmd.com/read/28624570/effects-of-intrauterine-contraception-on-the-vaginal-microbiota
#1
Christine M Bassis, Jenifer E Allsworth, Heather N Wahl, Daniel E Sack, Vincent B Young, Jason D Bell
OBJECTIVES: There have been conflicting reports of altered vaginal microbiota and infection susceptibility associated with contraception use. The objectives of this study were to determine if intrauterine contraception altered the vaginal microbiota and to compare the effects of a copper intrauterine device (Cu-IUD) and a levonorgestrel intrauterine system (LNG-IUS) on the vaginal microbiota. STUDY DESIGN: DNA was isolated from the vaginal swab samples of 76 women using Cu-IUD (n=36) or LNG-IUS (n=40) collected prior to insertion of intrauterine contraception (baseline) and at 6 months...
June 14, 2017: Contraception
https://www.readbyqxmd.com/read/28618723/evaluation-of-quality-of-life-and-cost-effectiveness-of-definitive-surgery-and-the-levonorgestrel-intrauterine-system-as-treatment-options-for-heavy-menstrual-bleeding
#2
Cevdet Adigüzel, Sevtap Seyfettinoğlu, Deniz Aka Satar, Sefa Arlier, Eda Eskimez, Fatma Kaya, Hakan Nazik
BACKGROUND/AIM: This study aimed to compare the levonorgestrel intrauterine system (LNG-IUS) with abdominal hysterectomy (TAH) and total laparoscopic hysterectomy (TLH) as first-line treatments for heavy menstrual bleeding (HMB). MATERIALS AND METHODS: Ninety-eight patients aged 20-55 years who complained of regular heavy menstrual bleeding were enrolled in the study. The TAH group included 29 patients, the LNG-IUS group included 34, and the TLH group included 35...
June 12, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28617060/levonorgestrel-releasing-intrauterine-system-lng-ius-12-for-prevention-of-pregnancy-for-up-to-five-years
#3
Anita L Nelson
A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of action as well as the results of the Phase II and III clinical trials of its efficacy, safety and tolerability. Expert Commentary: This new LNG-IUS 12 provides five-year contraceptive protection a pregnancy rate (less than 1%) in first year of use, which puts it into the top tier with the existing LNG-IUS 20 products; however, the LNG-IUS 12 does not have the high rates of amenorrhea often seen with the higher dose devices...
June 19, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28610898/immediate-versus-delayed-postpartum-use-of-levonorgestrel-contraceptive-implants-a-randomized-controlled-trial-in-uganda
#4
Sarah Averbach, Othman Kakaire, Herbert Kayiga, Felicia Lester, Abby Sokoloff, Josaphat Byamugisha, Christine Dehlendorf, Jody Steinauer
BACKGROUND: Use of long acting highly-effective contraception has the potential to improve women's ability to avoid short interpregnancy intervals, which are associated with an increased risk of maternal morbidity and mortality, and preterm delivery. In Uganda, contraceptive implants are not routinely available during the immediate postpartum period. OBJECTIVE: The purpose of this study was to compare the proportion of women using levonorgestrel contraceptive implants at six months after delivery in women randomized to immediate or delayed insertion...
June 10, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28601762/warming-modulates-the-effects-of-the-endocrine-disruptor-progestin-levonorgestrel-on-the-zebrafish-fitness-ovary-maturation-kinetics-and-reproduction-success
#5
P G Cardoso, D Rodrigues, T V Madureira, N Oliveira, M J Rocha, E Rocha
Interactive effects between multiple stressors, namely climate drivers (e.g., temperature) and chemical pollution (e.g., endocrine disruptors) are poorly studied. Here, it was for the first time evaluated the combinatory effects of temperature and a synthetic progestin, levonorgestrel (LNG), on the fitness and reproductive-related endpoints of zebrafish (Danio rerio). A multi-factorial design was implemented by manipulating both temperature [setting as baseline an ambient temperature of 27 °C, against warming (+3 °C)] and LNG levels (10 ngL(-1) and 1000 ngL(-1))...
June 8, 2017: Environmental Pollution
https://www.readbyqxmd.com/read/28600625/an-intravaginal-ring-that-releases-three-antiviral-agents-and-a-contraceptive-blocks-shiv-rt-infection-reduces-hsv-2-shedding-and-suppresses-hormonal-cycling-in-rhesus-macaques
#6
Nina Derby, Meropi Aravantinou, Jessica Kenney, Shweta R Ugaonkar, Asa Wesenberg, Jolanta Wilk, Larisa Kizima, Aixa Rodriguez, Shimin Zhang, Olga Mizenina, Keith Levendosky, Michael L Cooney, Samantha Seidor, Agegnehu Gettie, Brooke Grasperge, James Blanchard, Michael Piatak, Jeffrey D Lifson, José Fernández-Romero, Thomas M Zydowsky, Melissa Robbiani
Women globally need access to multipurpose prevention technologies (MPTs) that prevent human immunodeficiency virus (HIV), sexually transmitted infections that increase HIV acquisition/transmission risk, and unintended pregnancy. Seeking an MPT with activity against HIV, herpes simplex virus-2 (HSV-2), and human papillomavirus (HPV), we developed a prototype intravaginal ring (IVR), the MZCL IVR, which released the antiviral agents MIV-150, zinc acetate, and carrageenan (MZC for short) and the contraceptive levonorgestrel (LNG)...
June 9, 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/28596121/one-year-continuation-of-copper-or-levonorgestrel-intrauterine-devices-initiated-at-the-time-of-emergency-contraception
#7
J N Sanders, D K Turok, P A Royer, I S Thompson, L M Gawron, K E Storck
OBJECTIVE(S): This study compares one-year intrauterine device (IUD) continuation among women presenting for emergency contraception (EC) and initiating the copper (Cu T380A) IUD or the levonorgestrel (LNG) 52 mg IUD plus 1.5 mg oral LNG. STUDY DESIGN: This cohort study enrolled 188 women who presented at a single family planning clinic in Utah between June 2013 and September 2014 and selected either the Cu T380A IUD or LNG 52 mg IUD plus oral LNG for EC. Trained personnel followed participants by phone, text, or email for twelve months or until discontinuation occurred...
June 5, 2017: Contraception
https://www.readbyqxmd.com/read/28595627/trends-in-use-of-and-complications-from-intrauterine-contraceptive-devices-and-tubal-ligation-or-occlusion
#8
Brandon Howard, ElizaBeth Grubb, Maureen J Lage, Boxiong Tang
BACKGROUND: Long-acting reversible contraceptives such as intrauterine devices (IUDs) are highly effective in preventing pregnancy, cost effective, and increasing in popularity. It is unclear whether changes in IUD use are associated with changes in rates of irreversible tubal sterilization. In this analysis, we evaluate changes in rates of tubal sterilization, insertion of copper or levonorgestrel (LNG) IUDs, and related complications over time. METHODS: Data were obtained from a retrospective claims database (Optum(TM) Clinformatics(TM) Data Mart) of women aged 15 to 45 years who underwent insertion of copper or LNG IUD or tubal sterilization between 1/1/2006 and 12/31/2011...
June 8, 2017: Reproductive Health
https://www.readbyqxmd.com/read/28590560/routine-provision-of-intrauterine-contraception-at-elective-cesarean-section-in-a-national-public-health-service-a-service-evaluation
#9
Rebecca Heller, Anne Johnstone, Sharon T Cameron
INTRODUCTION: We conducted a prospective health service evaluation to assess the feasibility and acceptability of routinely offering insertion of intrauterine contraception (IUC) at cesarean section in a maternity setting in the UK. MATERIAL AND METHODS: One month before scheduled cesarean section, women were sent information about postpartum contraception including the option of insertion of IUC at cesarean. Women choosing IUC (copper intrauterine device or levonorgestrel intrauterine system) were followed up in person at six weeks; telephone contact was made at three, six and 12 months postpartum...
June 7, 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28586411/incidence-and-treatment-of-heavy-menstrual-bleeding-in-general-practice
#10
Marian J van den Brink, Anne Linde Saaltink, Feikje Groenhof, Boudewijn J Kollen, Marjolein Y Berger, Yvonne Lisman-van Leeuwen, Janny H Dekker
Background.: Heavy menstrual bleeding (HMB) is a common problem in women of reproductive age. In 2008, the Dutch guideline for general practitioners (GPs) was revised to recommend the levonorgestrel intrauterine system (LNG-IUS) as a first-choice treatment for HMB. However, GP prescribing practices have not been studied in depth. Objectives.: To investigate the incidence and initial treatment of HMB in general practice, and to identify if there were changes in prescribing practices after the revision of the national guideline in 2008...
June 6, 2017: Family Practice
https://www.readbyqxmd.com/read/28586290/non-contraceptive-benefits-of-intrauterine-levonorgestrel-administration-why-not
#11
Lorenzo Sabbioni, Felice Petraglia, Stefano Luisi
Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. However, there are countries in which their use is extremely limited by social and cultural factors. This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontraceptive benefits of intrauterine levonorgestrel in routinary practice. Medical diseases in which LNG-IUS represent a treatment include abnormal uterine bleeding, iron-deficiency anemia, endometrial hyperplasia, uterine fibroids, adenomyosis, endometriosis, and coagulopathies...
June 6, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28562472/gonadotropin-releasing-hormone-agonist-combined-with-a-levonorgestrel-releasing-intrauterine-system-or-letrozole-for-fertility-preserving-treatment-of-endometrial-carcinoma-and-complex-atypical-hyperplasia-in-young-women
#12
Huimei Zhou, Dongyan Cao, Jiaxin Yang, Keng Shen, Jinghe Lang
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety with gonadotropin-releasing hormone agonist (GnRHa) combined with a levonorgestrel-releasing intrauterine system or an aromatase inhibitor (letrozole) in young women with well-differentiated early endometrial carcinoma (EC) and complex atypical hyperplasia (CAH). METHODS: We performed a retrospective analysis including the clinical characteristics of 29 patients younger than 45 years with early well-differentiated endometrioid adenocarcinoma of the uterus (EC) or CAH who were treated at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, from January 2012 to April 2016...
May 29, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28553144/transdermal-delivery-of-combined-hormonal-contraception-a-review-of-the-current-literature
#13
REVIEW
Rosanna M Galzote, Sally Rafie, Rachel Teal, Sheila K Mody
The transdermal patch provides an effective and convenient option for hormonal contraception. The patch currently on the US market contains 150 µg norelgestromin and 35 µg ethinylestradiol (EE). The 20 cm(2) patch is applied once weekly for 3 weeks, followed by a patch-free week, for a 21-7 cycle. Typical failure rates are similar to that of combined oral contraceptives (COCs). Transdermal delivery results in less peaks and troughs of estrogen, but a higher total estrogen exposure compared with COCs. Though studies show mixed results, the risk of developing venous thromboembolism (VTE) is about twice as high with the patch as with COCs; however, the absolute risk of VTE remains low...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/28545268/-efficacy-and-impact-on-quality-of-life-of-different-drug-treatments-after-partial-resection-of-rectovaginal-endometriosis
#14
T Li, X X Xu, Y Dai, J J Zhang, J H Lang, J H Leng
Objective: To evaluate different postoperative medications as maintenance treatment for rectovaginal endometriosis (RVE) patients after conservative surgery. Methods: RVE patients who underwent transvaginal partial excision from January 2007 to September 2016 with regular outpatient follow-up were retrospectively screened. Those followed by a levonorgestrel-releasing intrauterine system (LNG-IUS) insertion or oral contraceptive drospirenone/ethinylestradiol (DRSP/EE) 3 mg/30 μg administration were enrolled...
May 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/28537655/comparative-effectiveness-and-impact-on-health-related-quality-of-life-of-hysterectomy-vs-levonorgestrel-intra-uterine-system-for-abnormal-uterine-bleeding
#15
G Cozza, A Pinto, V Giovanale, P Bianchi, A Guarino, R Marziani, A Frega, D Caserta
OBJECTIVE: To compare hysterectomy and levonorgestrel intra-uterine system (LNG-IUS) for the treatment of abnormal uterine bleeding (AUB) and iron deficiency anemia. PATIENTS AND METHODS: Retrospective study evaluating quality of life, sexual function, satisfaction and blood hemoglobin concentration improvement in 60 pre-menopausal women treated with hysterectomy or LNG-IUS. All analysis was performed with statistical software SPSS 21.0 (SPSS Inc., Chicago, IL, USA)...
May 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28536231/pregnant-with-a-perforated-levonorgestrel-intrauterine-system-and-visible-threads-at-the-cervical-os
#16
David L Howard, Lauren M Beasley
We present a case in which a patient presented with a pregnancy of unknown location and normally rising human chorionic gonadotropin (hCG) levels but with a levonorgestrel intrauterine device (LNG-IUD) present. The LNG-IUD had been placed 4.5 years ago. Although unintended, this pregnancy was desired. Strings were clearly visible and initial 2D ultrasound suggested intrauterine location of the LNG-IUD. The LNG-IUD could not be removed however. The patient was managed expectantly with close follow-up, serial beta-hCGs and serial ultrasounds until definitive diagnosis of the location of the pregnancy...
May 22, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28527109/erratum-to-clinical-pharmacokinetics-of-sacubitril-valsartan-lcz696-a-novel-angiotensin-receptor-neprilysin-inhibitor
#17
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu, Gangadhar Sunkara
Sacubitril/valsartan (LCZ696) is indicated for the treatment of heart failure with reduced ejection fraction. Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. With a twofold increase in dose, an increase in the area under the plasma concentration-time curve was proportional for sacubitril, ~1...
May 19, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28525380/comparison-among-fertility-sparing-therapies-for-well-differentiate-early-stage-endometrial-carcinoma-and-complex-atypical-hyperplasia
#18
REVIEW
Qing Zhang, Gonghua Qi, Margaux J Kanis, Ruifen Dong, Baoxia Cui, Xingsheng Yang, Beihua Kong
OBJECTIVE: To compare fertility-sparing therapies including oral progestogens, hysteroscopic resection (HR), and the levonorgestrel- releasing intrauterine system (LNG-IUS) in achieving disease regression, recurrence and live birth rate in well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia(CAH). STUDY DESIGN: This was a meta-analysis of previous studies focus on the fertility-sparing therapy for well differentiate early-stage endometrial carcinoma (eEC) and complex atypical hyperplasia (CAH)...
May 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28485895/with-smart-strategies-immediate-postpartum-larc-is-possible
#19
Ara Aiken
No abstract text is available yet for this article.
May 9, 2017: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28472576/ulipristal-acetate-an-update-for-australian-gps
#20
Danielle Mazza
BACKGROUND: In Australia, use and understanding of emergency contraception among women remains relatively low. This is despite the introduction of levonorgestrel emergency contraceptive pills (ECPs) more than a decade ago. In April 2016, a new ECP with the active ingredient ulipristal acetate became available in Australia. OBJECTIVE: The aims of this article are to increase understanding of the recently introduced ulipristal acetate ECP, including its safety profile, effi-cacy and special considerations; dispel common myths and misconceptions about emergency contraception; and to provide guidance on emergency contraceptive management in general practice, considering the recent advances...
2017: Australian Family Physician
keyword
keyword
20950
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"